(CNO) CNO Financial - Overview

Sector: Financial Services | Industry: Insurance - Life | Exchange: NYSE (USA) | Market Cap: 3.906m USD | Total Return: -1.9% in 12m

Stock Health Insurance, Annuities, Life Insurance, Financial Services
Total Rating 39
Risk 73
Buy Signal 0.40
Insurance - Life +10.2
Life & Health Insurance +8.1
Market Cap: 3,906m
Avg Trading Vol: 23.0M USD
ATR: 2.69%
Peers RS (IBD): 50.0
Risk 5d forecast
Volatility28.1%
Rel. Tail Risk-2.74%
Reward TTM
Sharpe Ratio-0.06
Alpha-14.95
Character TTM
Beta0.873
Beta Downside1.347
Drawdowns 3y
Max DD15.86%
CAGR/Max DD1.51
EPS (Earnings per Share) EPS (Earnings per Share) of CNO over the last years for every Quarter: "2021-03": 0.55, "2021-06": 0.66, "2021-09": 0.72, "2021-12": 0.87, "2022-03": 0.42, "2022-06": 0.85, "2022-09": 0.49, "2022-12": 0.56, "2023-03": 0.51, "2023-06": 0.54, "2023-09": 0.88, "2023-12": 1.18, "2024-03": 0.52, "2024-06": 1.05, "2024-09": 1.11, "2024-12": 1.31, "2025-03": 0.79, "2025-06": 0.87, "2025-09": 1.29, "2025-12": 1.47,
EPS CAGR: 39.66%
EPS Trend: 74.4%
Last SUE: 1.37
Qual. Beats: 2
Revenue Revenue of CNO over the last years for every Quarter: 2021-03: 1006, 2021-06: 1073.1, 2021-09: 968.3, 2021-12: 1074.8, 2022-03: 842.9, 2022-06: 855, 2022-09: 905.3, 2022-12: 973.6, 2023-03: 1006, 2023-06: 1022.8, 2023-09: 947.5, 2023-12: 1170.5, 2024-03: 1152.7, 2024-06: 1066.2, 2024-09: 1129.5, 2024-12: 1097.2, 2025-03: 1004.1, 2025-06: 1151.5, 2025-09: 1188.7, 2025-12: 1143.1,
Rev. CAGR: 8.46%
Rev. Trend: 82.5%
Last SUE: 2.63
Qual. Beats: 2
Description: CNO CNO Financial March 05, 2026

CNO Financial Group, Inc. (CNO) provides health, life, and annuity products, along with financial services. The company targets middle-income pre-retiree and retired Americans in the United States.

CNOs product offerings include Medicare supplement, long-term care, and various life insurance policies. They also offer annuities such as fixed indexed and fixed interest options. These products are distributed through multiple channels, including agents, virtual platforms, and online.

The company also sells voluntary benefit life and health insurance products to businesses and groups. This business model in the life and health insurance sector typically involves long-term contracts and recurring premium payments. CNO operates under brand names like Bankers Life, Washington National, and Colonial Penn. For more detailed analysis, consider exploring CNOs financial statements on ValueRay.

Headlines to Watch Out For
  • Interest rate fluctuations impact annuity and life insurance product profitability
  • Healthcare policy changes affect Medicare supplement and long-term care sales
  • Middle-income consumer spending directly influences insurance product demand
  • Agent productivity and retention drive new policy sales growth
  • Regulatory changes in insurance industry increase compliance costs
Piotroski VR‑10 (Strict, 0-10) 2.0
Net Income: 221.5m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.08 > 1.0
NWC/Revenue: 19.43% < 20% (prev 7.33%; Δ 12.10% < -1%)
CFO/TA 0.02 > 3% & CFO 675.7m > Net Income 221.5m
Net Debt (3.10b) to EBITDA (750.9m): 4.12 < 3
Current Ratio: 8.83 > 1.5 & < 3
Outstanding Shares: last quarter (97.3m) vs 12m ago -8.33% < -2%
Gross Margin: 40.15% > 18% (prev 0.41%; Δ 3.97k% > 0.5%)
Asset Turnover: 11.68% > 50% (prev 11.74%; Δ -0.06% > 0%)
Interest Coverage Ratio: 1.51 > 6 (EBITDA TTM 750.9m / Interest Expense TTM 230.9m)
Altman Z'' 0.45
A: 0.02 (Total Current Assets 983.5m - Total Current Liabilities 111.4m) / Total Assets 38.97b
B: 0.06 (Retained Earnings 2.42b / Total Assets 38.97b)
C: 0.01 (EBIT TTM 349.6m / Avg Total Assets 38.41b)
D: 0.04 (Book Value of Equity 1.30b / Total Liabilities 36.33b)
Altman-Z'' Score: 0.45 = B
Beneish M
DSRI: 0.99 (Receivables 4.68b/4.67b, Revenue 4.49b/4.45b)
GMI: 1.02 (GM 40.15% / 41.03%)
AQI: none (AQ_t none / AQ_t-1 none)
SGI: 1.01 (Revenue 4.49b / 4.45b)
TATA: -0.01 (NI 221.5m - CFO 675.7m) / TA 38.97b)
Beneish M-Score: cannot calculate (missing components)
What is the price of CNO shares? As of March 31, 2026, the stock is trading at USD 40.18 with a total of 367,041 shares traded.
Over the past week, the price has changed by -0.89%, over one month by -3.50%, over three months by -5.71% and over the past year by -1.86%.
Is CNO a buy, sell or hold? CNO Financial has received a consensus analysts rating of 2.83. Therefor, it is recommend to hold CNO.
  • StrongBuy: 0
  • Buy: 1
  • Hold: 4
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the CNO price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 47.6 18.5%
Analysts Target Price 47.6 18.5%
CNO Fundamental Data Overview March 28, 2026
P/E Trailing = 17.8087
P/E Forward = 9.7087
P/S = 0.8704
P/B = 1.4201
P/EG = 1.287
Revenue TTM = 4.49b USD
EBIT TTM = 349.6m USD
EBITDA TTM = 750.9m USD
Long Term Debt = 4.05b USD (from longTermDebt, last quarter)
 Short Term Debt = unknown (none)
 Debt = 4.05b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = -915.7m USD (3.91b + Debt 4.05b - CCE 8.87b)
Interest Coverage Ratio = 1.51 (Ebit TTM 349.6m / Interest Expense TTM 230.9m)
EV/FCF = -1.36x (Enterprise Value -915.7m / FCF TTM 675.7m)
FCF Yield = -73.79% (FCF TTM 675.7m / Enterprise Value -915.7m)
FCF Margin = 15.06% (FCF TTM 675.7m / Revenue TTM 4.49b)
Net Margin = 4.94% (Net Income TTM 221.5m / Revenue TTM 4.49b)
Gross Margin = 40.15% ((Revenue TTM 4.49b - Cost of Revenue TTM 2.69b) / Revenue TTM)
Gross Margin QoQ = 47.27% (prev 38.69%)
 Tobins Q-Ratio = -0.02 (set to none) (Enterprise Value -915.7m / Total Assets 38.97b)
 Interest Expense / Debt = 1.31% (Interest Expense 53.2m / Debt 4.05b)
Taxrate = 16.61% (18.5m / 111.4m)
NOPAT = 291.5m (EBIT 349.6m * (1 - 16.61%))
Current Ratio = 8.83 (Total Current Assets 983.5m / Total Current Liabilities 111.4m)
Debt / Equity = 1.54 (Debt 4.05b / totalStockholderEquity, last quarter 2.64b)
Debt / EBITDA = 4.12 (Net Debt 3.10b / EBITDA 750.9m)
Debt / FCF = 4.58 (Net Debt 3.10b / FCF TTM 675.7m)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.58% (Net Income 221.5m / Total Assets 38.97b)
RoE = 8.60% (Net Income TTM 221.5m / Total Stockholder Equity 2.58b)
RoCE = 5.28% (EBIT 349.6m / Capital Employed (Equity 2.58b + L.T.Debt 4.05b))
RoIC = 4.33% (NOPAT 291.5m / Invested Capital 6.73b)
WACC = 5.00% (E(3.91b)/V(7.96b) * Re(9.05%) + D(4.05b)/V(7.96b) * Rd(1.31%) * (1-Tc(0.17)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -7.48%
[DCF] Terminal Value 87.05% ; FCFF base≈656.5m ; Y1≈707.7m ; Y5≈872.3m
[DCF] Fair Price = 239.9 (EV 25.71b - Net Debt 3.10b = Equity 22.61b / Shares 94.3m; r=6.0% [WACC]; 5y FCF grow 8.78% → 3.0% )
EPS Correlation: 74.39 | EPS CAGR: 39.66% | SUE: 1.37 | # QB: 2
Revenue Correlation: 82.47 | Revenue CAGR: 8.46% | SUE: 2.63 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.05 | Chg7d=+0.010 | Chg30d=+0.007 | Revisions Net=+0 | Analysts=3
EPS current Year (2026-12-31): EPS=4.40 | Chg7d=-0.009 | Chg30d=+0.007 | Revisions Net=+2 | Growth EPS=-0.1% | Growth Revenue=-9.7%
EPS next Year (2027-12-31): EPS=4.88 | Chg7d=+0.003 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+11.1% | Growth Revenue=+3.3%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 9.1% - Earnings Yield 5.6%)
[Growth] Growth Spread = -16.4% (Analyst -12.9% - Implied 3.4%)
Additional Sources for CNO Stock Fund Manager Positions: Dataroma · Stockcircle